Benjamin Hohl, CHIEF FINANCIAL OFFICER at Enliven Therapeutics, Inc. (ELVN), sold 21,706 shares at $27.51 ($597K) on 2024-10-04, disclosed to the SEC on 2024-10-08.
Scheduled sale ($597k) by CHIEF FINANCIAL OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $27.51 | 10,218 | $281K | 47.1% |
| 2 | $27.51 | 10,218 | $281K | 47.1% |
| 3 | $27.51 | 1,270 | $35K | 5.9% |
| Total | $27.51 avg | 21,706 | $597K | 100% |
| Filing → |
| ELVN | SELL | 2026-07-21 | $317K | — | Filing → |
| ELVN | SELL | 2026-06-22 | $264K | — | Filing → |
| ELVN | SELL | 2026-03-10 | $296K | — | Filing → |